Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting
Cogent Biosciences (Nasdaq: COGT) has announced an upcoming poster presentation featuring bezuclastinib at the 2025 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI) in San Diego. The presentation will focus on a subgroup of patients who received 100mg bezuclastinib for at least 48 weeks in the ongoing Summit Trial, highlighting long-term symptomatic benefits.
The poster, titled 'Efficacy and Safety Results of Adult Patients with NonAdvanced Systemic Mastocytosis Receiving Bezuclastinib 100 mg in the Ongoing Summit Trial: A Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial of Bezuclastinib,' will be presented on March 1, 2025, from 9:45-10:45am PT at the San Diego Convention Center.
Cogent Biosciences (Nasdaq: COGT) ha annunciato una prossima presentazione di poster riguardante il bezuclastinib al 2025 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI) a San Diego. La presentazione si concentrerà su un sottogruppo di pazienti che hanno ricevuto 100 mg di bezuclastinib per almeno 48 settimane nello studio Summit in corso, evidenziando i benefici sintomatici a lungo termine.
Il poster, intitolato 'Efficacia e Risultati di Sicurezza di Pazienti Adulti con Mastocitosi Sistemica Non Avanzata Riceventi Bezuclastinib 100 mg nello Studio Summit in Corso: Uno Studio Clinico di Fase 2 Randomizzato, In Doppio Cieco, Controllato con Placebo sul Bezuclastinib,' sarà presentato il 1 marzo 2025, dalle 9:45 alle 10:45 PT presso il Centro Congressi di San Diego.
Cogent Biosciences (Nasdaq: COGT) ha anunciado una próxima presentación de póster sobre bezuclastinib en la Reunión Anual de la Academia Americana de Alergia, Asma e Inmunología (AAAAI) de 2025 en San Diego. La presentación se centrará en un subgrupo de pacientes que recibieron 100 mg de bezuclastinib durante al menos 48 semanas en el ensayo Summit en curso, destacando los beneficios sintomáticos a largo plazo.
El póster, titulado 'Resultados de Eficacia y Seguridad en Pacientes Adultos con Mastocitosis Sistémica No Avanzada Recibiendo Bezuclastinib 100 mg en el Ensayo Summit en Curso: Un Ensayo Clínico de Fase 2 Aleatorizado, Doble Ciego y Controlado con Placebo sobre Bezuclastinib,' será presentado el 1 de marzo de 2025, de 9:45 a 10:45 a.m. PT en el Centro de Convenciones de San Diego.
Cogent Biosciences (Nasdaq: COGT)는 샌디에이고에서 열리는 2025 미국 알레르기 천식 및 면역학회 연례 회의 (AAAAI)에서 bezuclastinib에 대한 포스터 발표를 할 것이라고 발표했습니다. 발표는 현재 진행 중인 Summit 시험에서 최소 48주 동안 100mg의 bezuclastinib을 받은 환자 하위 그룹에 초점을 맞추어 장기적인 증상 개선 효과를 강조할 것입니다.
이 포스터의 제목은 '현재 진행 중인 Summit 시험에서 비고급 체세포 비대증 성인 환자에게 Bezuclastinib 100 mg의 효능 및 안전성 결과: Bezuclastinib에 대한 무작위 이중 맹검 위약 대조 2상 임상 시험'이며, 2025년 3월 1일 오전 9:45 부터 10:45 까지 PT 샌디에이고 컨벤션 센터에서 발표될 예정입니다.
Cogent Biosciences (Nasdaq: COGT) a annoncé une prochaine présentation de poster portant sur le bezuclastinib lors de la Réunion Annuelle de l'Académie Américaine d'Allergie, d'Asthme et d'Immunologie (AAAAI) de 2025 à San Diego. La présentation se concentrera sur un sous-groupe de patients ayant reçu 100 mg de bezuclastinib pendant au moins 48 semaines dans l'essai en cours Summit, mettant en évidence les avantages symptomatiques à long terme.
Le poster, intitulé 'Résultats d'Efficacité et de Sécurité chez les Patients Adultes atteints de Mastocytose Systémique Non Avancée Recevant du Bezuclastinib 100 mg dans l'Éssai en Cours Summit : un Essai Clinique de Phase 2 Randomisé, en Double Aveugle, Contrôlé par Placebo sur le Bezuclastinib,' sera présenté le 1er mars 2025, de 9h45 à 10h45 PT au Centre de Congrès de San Diego.
Cogent Biosciences (Nasdaq: COGT) hat eine bevorstehende Posterpräsentation zu Bezuclastinib auf dem 2025 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI) in San Diego angekündigt. Die Präsentation wird sich auf eine Untergruppe von Patienten konzentrieren, die 100 mg Bezuclastinib über mindestens 48 Wochen in der laufenden Summit-Studie erhalten haben, wobei die langfristigen symptomatischen Vorteile hervorgehoben werden.
Das Poster mit dem Titel 'Wirksamkeits- und Sicherheitsresultate von erwachsenen Patienten mit nicht fortgeschrittener systemischer Mastzytose, die Bezuclastinib 100 mg in der laufenden Summit-Studie erhalten: Eine randomisierte, doppelblinde, placebo-kontrollierte Phase-2-Studie zu Bezuclastinib' wird am 1. März 2025 von 9:45 bis 10:45 Uhr PT im San Diego Convention Center präsentiert.
- None.
- None.
WALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced an upcoming poster for bezuclastinib at the 2025 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI) being held in San Diego, CA, February 28-March 3, 2025.
The focus of the presentation will be on the subgroup of patients who have received 100mg bezuclastinib for at least 48 weeks to highlight the symptomatic benefits of long-term use.
Poster Details
Poster Presentation Title: Efficacy and Safety Results of Adult Patients with NonAdvanced Systemic Mastocytosis Receiving Bezuclastinib 100 mg in the Ongoing Summit Trial: A Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial of Bezuclastinib
Session Date and Time: March 1, 2025 – 9:45am – 10:45am PT (12:45pm – 1:45pm ET)
Session Title: Novel Mechanisms of Mast Cells, Basophils and IgE
Poster Number: 520
Location: San Diego Convention Center, Ground Level, Hall A
About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2 inhibitor. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα and KRAS. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X (formerly known as Twitter) and LinkedIn. Information that may be important to investors will be routinely posted on our website and X.
Contact:
Christi Waarich
Senior Director, Investor Relations
christi.waarich@cogentbio.com
617-830-1653
FAQ
What are the key findings from Cogent Biosciences' (COGT) bezuclastinib Summit Trial in NonAdvanced Systemic Mastocytosis?
When and where will Cogent Biosciences (COGT) present their bezuclastinib trial results?
What is the dosage and duration of bezuclastinib treatment being studied in COGT's Summit Trial?
What type of clinical trial is the COGT Summit Trial for bezuclastinib?
